/
Immunology
Chronic Granulomatous Disease
22
Pipeline Programs↗
15
Active Trials↗
10
Companies Involved↗
Chronic Granulomatous Disease is an emerging landscape with 22 programs across 10 companies. The most active players are Roche, Pfizer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 13
Phase 210
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
17programs
Small molecule1059%
Monoclonal antibody318%
Protein / enzyme212%
Cell therapy16%
Gene therapy16%
Modality classified for 95% of 22 pipeline programs.
Analysis
Trial Status
33
clinical trials
Completed10 · 30%
Recruiting7 · 21%
Active, not recruiting5 · 15%
Terminated5 · 15%
Enrolling by invitation2 · 6%
Unknown status2 · 6%
Other2 · 6%
Clinical Trials
Trial Activity
33 trials
NADPH Oxidase Correction in mRNA Transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05189925·25 enrolled
Screening and Baseline Assessment of Patients With Abnormalities of Immune Function
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00128973·3,500 enrolled
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05463133·50 enrolled
Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05333471·20 enrolled
Haploidentical Transplant for Patients With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03910452·4 enrolled
High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT02629120·45 enrolled
Pilot Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05600907·7 enrolled
Part B- Phase I/II, Non-Randomized, Single Site Study, Open-label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Enrolling by invitation·National Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT07113743·10 enrolled
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
Enrolling by invitation·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05104723·20 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)